Navigation Links
Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400
Date:3/7/2008

SANTA CLARA, Calif., March 7 /PRNewswire/ -- Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life sciences process applications, and Nova Biomedical, Waltham, MA, a world leader in biotechnology process monitoring announced the first TruBio(TM) OS plug-in for OPC connectivity between TruBio(TM) OS and Nova BioProfile 400, 100 Plus, Basic 4 and Basic 2 analyzers. Both companies confirmed that a TruBio(TM) OS plug-in for OPC connectivity to the Nova Flex is currently in development.

OPC (Openness, Productivity and Collaboration) has become the de facto standard for data exchange in process control systems. It has been adopted by the majority of the control system manufacturers in the bioprocess industry and has proven to be a reliable method for sharing information across different hardware platforms.

Automatic data exchange using OPC between a lab analyzer and control system reduces errors and time delays of manual sampling, and provides automated reporting of results. It also allows the control system to adjust process parameters without a 24/7 operator presence, and, in the event of process alarm conditions, alerts off-site personnel and/or takes automatic corrective action.

This level of integration enables direct consolidation of off-line lab analyzer results into existing historical data collection, automates batch report generation, and creates a complete electronic record. Printouts of standalone analyzer results do not have to be manually attached or tracked with electronic batch reports that control systems already provide.

"Taking advantage of OPC connectivity between Nova analyzers and the Finesse bioprocess control system will improve quality and yield, while reducing operating costs. For example, programming a Nova analyzer to automatically standardize an in-situ probe, or using the resulting sample data in real-time control algorithms, will increase both process understanding and control
'/>"/>

SOURCE Finesse Solutions, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Finesse Solutions Expands by Opening Sales and Service Centers
2. Finesse Introduces TruBio(TM) IOQ
3. Cascade Microtech Introduces Worlds First 45 nm-capable DC/RF Parametric Probe Card Solutions, Lowers Cost of Ownership
4. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
5. Senetek PLC Announces Appointments of Key Personnel
6. Iomai Announces Year-End 2007 Financial Results and Business Progress
7. Dragon announces new product launch; increase in annual production output capacity
8. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
9. China Yingxia International Announces Q4 and FY 2007 Estimates
10. Bristol-Myers Squibb Announces Dividend
11. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4